Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
Recruiting · NCT06160791 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) | Hemic and Lymphatic Diseases, Lymphohistiocytosis, Hemophagocytic, histiocytosis, lymphatic system disorder, non-Langerhans cell histiocytosis | Recruiting | Phase 2 | 2026-09-21 | NCT06160791 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| Jerry Lee, MD, MSc, MPhil | 1 |
| UC Hematological Malignancies Consortium (UCHMC) | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | United States | 299 |
| University of California, Irvine | Irvine | United States | 32 |
| University of California, San Diego | San Diego | United States | 29 |
| University of California, San Francisco | San Francisco | United States | 294 |